Le immunoglobuline nella terapia delle malattie reumatiche

Descrizione di un caso di vasculite cutanea e revisione della letteratura

Translated title of the contribution: Intravenous immunoglobulin for rheumatic diseases: Description of a case and review of the literature

Bianca Marasini, Marco Massarotti

Research output: Contribution to journalArticle

Abstract

Intravenous immunoglobulins (IVIG) have become an important therapeutic tool not only for patients with idiopathic and acquired immunodeficiencies, but also in a number of immunorheumatic conditions. The mechanisms by which IVIG exert their immunoregulatory effects are not completely defined and probably differ in the various diseases. Although generally well tolerated, since severe side-effects can occur, patients at risk (IgA deficient patients, older patients, patients with kidney or heart disease) must be identified to minimize adverse events. At present, ANCA-associated vasculitis, dermatomyositis and probably fibrosing conditions may represent the rheumatic diseases for which IVIG efficacy seems to be well documented. Controlled trials are however needed to provide guidelines for IVIG use in rheumatic diseases.

Original languageItalian
Pages (from-to)1-9
Number of pages9
JournalTrends in Medicine
Volume7
Issue number1
Publication statusPublished - Jan 2007

Fingerprint

Intravenous Immunoglobulins
Rheumatic Diseases
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Dermatomyositis
Kidney Diseases
Immunoglobulin A
Heart Diseases
Guidelines

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology (medical)

Cite this

Le immunoglobuline nella terapia delle malattie reumatiche : Descrizione di un caso di vasculite cutanea e revisione della letteratura. / Marasini, Bianca; Massarotti, Marco.

In: Trends in Medicine, Vol. 7, No. 1, 01.2007, p. 1-9.

Research output: Contribution to journalArticle

@article{f48b094afe694a95b36608580143336c,
title = "Le immunoglobuline nella terapia delle malattie reumatiche: Descrizione di un caso di vasculite cutanea e revisione della letteratura",
abstract = "Intravenous immunoglobulins (IVIG) have become an important therapeutic tool not only for patients with idiopathic and acquired immunodeficiencies, but also in a number of immunorheumatic conditions. The mechanisms by which IVIG exert their immunoregulatory effects are not completely defined and probably differ in the various diseases. Although generally well tolerated, since severe side-effects can occur, patients at risk (IgA deficient patients, older patients, patients with kidney or heart disease) must be identified to minimize adverse events. At present, ANCA-associated vasculitis, dermatomyositis and probably fibrosing conditions may represent the rheumatic diseases for which IVIG efficacy seems to be well documented. Controlled trials are however needed to provide guidelines for IVIG use in rheumatic diseases.",
author = "Bianca Marasini and Marco Massarotti",
year = "2007",
month = "1",
language = "Italian",
volume = "7",
pages = "1--9",
journal = "Trends in Medicine",
issn = "1594-2848",
publisher = "Pharma Project Group Edizioni Scientifiche (PPG)",
number = "1",

}

TY - JOUR

T1 - Le immunoglobuline nella terapia delle malattie reumatiche

T2 - Descrizione di un caso di vasculite cutanea e revisione della letteratura

AU - Marasini, Bianca

AU - Massarotti, Marco

PY - 2007/1

Y1 - 2007/1

N2 - Intravenous immunoglobulins (IVIG) have become an important therapeutic tool not only for patients with idiopathic and acquired immunodeficiencies, but also in a number of immunorheumatic conditions. The mechanisms by which IVIG exert their immunoregulatory effects are not completely defined and probably differ in the various diseases. Although generally well tolerated, since severe side-effects can occur, patients at risk (IgA deficient patients, older patients, patients with kidney or heart disease) must be identified to minimize adverse events. At present, ANCA-associated vasculitis, dermatomyositis and probably fibrosing conditions may represent the rheumatic diseases for which IVIG efficacy seems to be well documented. Controlled trials are however needed to provide guidelines for IVIG use in rheumatic diseases.

AB - Intravenous immunoglobulins (IVIG) have become an important therapeutic tool not only for patients with idiopathic and acquired immunodeficiencies, but also in a number of immunorheumatic conditions. The mechanisms by which IVIG exert their immunoregulatory effects are not completely defined and probably differ in the various diseases. Although generally well tolerated, since severe side-effects can occur, patients at risk (IgA deficient patients, older patients, patients with kidney or heart disease) must be identified to minimize adverse events. At present, ANCA-associated vasculitis, dermatomyositis and probably fibrosing conditions may represent the rheumatic diseases for which IVIG efficacy seems to be well documented. Controlled trials are however needed to provide guidelines for IVIG use in rheumatic diseases.

UR - http://www.scopus.com/inward/record.url?scp=33846980811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846980811&partnerID=8YFLogxK

M3 - Articolo

VL - 7

SP - 1

EP - 9

JO - Trends in Medicine

JF - Trends in Medicine

SN - 1594-2848

IS - 1

ER -